MedTrace Logo

Single Injection Infromedial Peribulbar Injection in Lacrimal Duct

NCT04859049 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-09-21

No results posted yet for this study

Summary

infromedial injection of 3 ml local anesthetic drugs and assessing the pain during lacrimal duct intubation and probability of false tracking

Conditions

  • Pain Due to Certain Specified Procedures

Interventions

PROCEDURE

infromedial single injection

Group 1: We used a 25G/ 1" length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid, 0.5ml below the inferior punctum in the lower lid medial margin.

PROCEDURE

medial canthus injection

: We used a 25G/ 1" length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid classical medial canthal injection

Sponsors & Collaborators

  • Research Institute of Ophthalmology, Egypt

    lead OTHER

Principal Investigators

  • abeer salem, MD · research institute of ophthalmology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04859049 on ClinicalTrials.gov